新英格兰医学期刊：ALEX 实验确认罗氏药物艾乐替尼医治肺癌好于克唑替尼 。
摘 要：克唑替尼肺癌脑转移。《新英格兰医科学杂志》2022年6月6日线上先给http://www.nejm.org/doi/full/10.1056/NEJMoa1704795

在未医治过的ALK呈阳性非小细胞肺癌中艾乐替尼较为克唑替尼

环境艾乐替尼（alectinib）是一种相对高度目的性的间转性淋巴肿瘤蛋白激酶（ALK）缓聚剂，在ALK呈阳性非小细胞肺癌的诊治中已展现出全身及神经中枢系统软件（CNS）的治疗效果。在以往未医治过的晚中后期ALK呈阳性非小细胞肺癌病患者中，这种病患者包含无症状的神经中枢体系迁移蔓延病患者，大家对艾乐替尼与克唑替尼相较为，开展了科学研究。方式 在一项随机化、对外开放标识的3期临床试验中，大家任意入组了303例以往没经医治的晚中后期ALK呈阳性非小细胞肺癌病患者，接纳艾乐替尼（600mg，每日2次）或克唑替尼（250mg，每日2次）。关键终点站是学者评定的无进度存活時间。主次终点站是单独审批联合会评定的无进度存活時间、发生神经中枢系统软件发展的時间、客观性反映率及总存活時间。結果克唑替尼组负相关随诊期17.6月、艾乐替尼组18.6月，随诊时间范围，艾乐替尼组152名病患者中有62例（41%）产生恶性肿瘤进度或是过世(过虑词)，克唑替尼组151名病患者中有102例（68%）。学者评定的无进度存活時间艾乐替尼组显然超过克唑替尼组（艾乐替尼组12个月无进度(过虑词)存活概率68.4%[95%可信区间CI,61.0-75.9],较为克唑替尼组48.7%[95%CI,40.4-56.9]，病症进度或过世的危险性比0.47[95%CI,0.34-0.65]，P<0.001）；艾乐替尼组负相关无进度存活時间并未做到。单独审查联合会评定的无进度存活時间結果与关键终点站結果一致。艾乐替尼组总共18名病患者（12%）发生了神经中枢系统软件进度(过虑词)，与之对比，克唑替尼组是68名（45%）（得病缘故非特异风险比，0.16；95%CI，0.10-0.28；P<0.001）。艾乐替尼组126名病患者医治合理（反映率，82.9%；95%CI，76.0-88.5），克唑替尼组是114名（反映率，75.5%；95%CI，67.8-82.1）（P=0.09）。艾乐替尼组3至5级副作用较少（41%较为克唑替尼组50%）。结果在ALK呈阳性非小细胞肺癌的起始医治中，与克唑替尼对比，艾乐替尼主要表现出更快的治疗效果、更低的毒副作用。《壹篇》李振爽

Alectinib versus Crizotinib in UntreatedALK-Positive Non–Small-Cell Lung Cancer

June 6, 2017DOI: 10.1056/NEJMoa1704795BackgroundAlectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease.MethodsIn a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee–assessed progression-free survival, time to CNS progression, objective response rate, and overall survival.ResultsDuring a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee–assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib).ConclusionsAs compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann–La Roche; ALEX ClinicalTrials.gov number, NCT02075840.)《壹篇》系关键朝向医护人员的服务性【微信号码：yaodaoyaofang】，不因盈利为目地，不开展一切有偿服务资询和服务项目，不销售一切商品，与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络，都不意味着一切官方网学好发音。文章照片均来源于互联网，不做商业行为，若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信：india2080】、称赞和分享——【手机微信：india2080】是一种心态和适用。
药道网给予近期的药物新闻资讯，聚集 印度的全世界海淘药店：克唑替尼使用方法使用量。